NCT05217693招募中1 期
A Phase I First-in-human, Open Label, Multicenter, Dose Escalation and Cohort Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of BB-1705 in Patients With Locally Advanced/Metastatic Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 288
- 试验地点
- 7
- 主要终点
- Number of subjects with adverse events and serious adverse events
研究概览
简要总结
The study consists of two phases: dose-escalation (Phase I) and cohort expansion (Phase II).
详细描述
Phase Ia is a dose escalation study to assess the safety and tolerability, and to determine the MTD or MAD and RP2D of BB-1705.
Phase Ib is a cohort expansion study to explore one or more RP2Ds to further assess safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. Patients with locally advanced and unresectable or metastatic solid tumors who have progressed on prior lines of standard of care therapies will be enrolled in this study if eligible.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 78 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide written informed consent form (ICF) for the trial.
- •Adult patients ≥ 18 years at the time of signing ICF.
- •Patient must have a histologically or cytologically confirmed, locally advanced, unresectable, or metastatic solid tumors:
- •At least one measurable lesion as defined per RECIST Version 1.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Life expectancy ≥12 weeks.
- •Adequate organ function as indicated by the following laboratory values (had not received blood transfusion, EPO, G-CSF, or other medical support within the 14 days before the administration of BB-1705):
- •Women of childbearing potential and males with fertile female partner must be willing to use currently accepted reliable contraception method throughout the treatment period from ICF signed and for at least 6 months following the last dose of BB-
- •These measures include, but are not limited to, oral or implantable injections of hormonal contraceptives; intrauterine birth control ring or placement of IUS intrauterine device); or use of barrier methods such as condoms or septum and spermicide products. Postmenopausal women over 50 years of age must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Women of childbearing potential must have a negative pregnancy test ≤ 7 days prior to the first dose of investigational product.
排除标准
- •Receiving cancer therapy (chemotherapy or other systemic anti-cancer therapies, immunotherapy, radiation therapy, or surgery) at the time of enrollment
- •Prior history of other malignancies.
- •Not recovered to baseline or ≤ grade 1 adverse events from prior anti-cancer treatment.
- •Major surgery within 4 weeks and minor surgery within 2 weeks before the first dose or not fully recovered from surgery; or surgery planned during the time the patient is expected to participate in the study
- •Grade 2 or higher peripheral neuropathy.
- •Active pneumonitis/interstitial lung disease (ILD), a history of pneumonitis/ILD that required systemic steroids, received radiotherapy to lung field within 12 months before the first dose of study intervention, or current clinically relevant-lung disease
- •Symptomatic or untreated CNS metastases, or those requiring ongoing treatment for CNS metastases, including steroids (>10 mg of prednisone or 4 mg of dexamethasone) and antiepileptic agents.
- •Any other serious ongoing underlying medical conditions, including but not limited to, uncontrolled diabetes mellitus, active uncontrolled infection, vaccination within 4 weeks, active gastric ulcer, uncontrolled seizures, cerebrovascular incidents within 6 months of study entry, gastrointestinal bleeding within 3 months of study entry, severe signs and symptoms of coagulation and clotting disorders.
- •QTc interval ≥450 ms for male or ≥470 ms for female (Fridericia's formula) and patients with congenital long QT syndrome.
研究组 & 干预措施
dose escalation
Experimental
Drug: BB-1705 BB-1705 will be administered as an intravenous infusion by Q3W for 8cycles
干预措施: BB-1705 (Drug)
cohort expansion
Experimental
BB-1705 will be administered as an intravenous infusion by Q3W for 8cycles
干预措施: BB-1705 (Drug)
结局指标
主要结局
Number of subjects with adverse events and serious adverse events
时间窗: up to 2 years
To evaluate the safety and tolerability of BB-1705
Number of subjects with dose limiting toxicity (DLT)
时间窗: Cycle 1. Duration of each cycle is 21 days.
Subjects are evaluated for all study drug related and treatment emergent toxicities based on the National Cancer Institute Common Toxicity Criteria for adverse events (NCI-CTCAE)
MTD
时间窗: Cycle 1. Duration of each cycle is 21 days.
MTD is defined as the highest dose level at which no more than 1 out of 6 subjects experiences a DLT during the first cycle.
次要结局
- Area under the serum concentration time curve from time 0 extrapolated to infinity (AUC0-inf)(Pre-dose and post-dose during Cycle 1 through Cycle 8. Duration of each cycle is 21 days.)
- Objective response(Every 6 weeks within 6 months and approximately every 9 weeks thereafter (up to 2 years))
- Progression Free Survival(Every 6 weeks within 6 months and approximately every 9 weeks thereafter (up to 2 years))
- Duration of Response(Every 6 weeks within 6 months and approximately every 9 weeks thereafter (up to 2 years))
- Incidence of anti-drug antibodies(Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of Cycles 2, 4, 6, and 8. Duration of each cycle is 21 days.)
- Maximum observed plasma concentration (Cmax)(Pre-dose and post-dose during Cycle 1 through Cycle 8. Duration of each cycle is 21 days.)
研究者
研究点 (7)
Loading locations...
相似试验
Unknown
1 期
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid TumorsReceptor, ErbB-2NCT05145179Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.162
尚未招募
1 期
A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaLocalized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaExpressing Human Epidermal Growth Factor Receptor-2 (HER-2)Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the PastNCT06577376Shanghai Runshi Pharmaceutical Technology Co., Ltd252
招募中
1 期
A Study of DM002 in Patients With Advanced Solid TumorsProstatic NeoplasmsOvarian NeoplasmsEndometrial NeoplasmsSolid CarcinomaColorectal NeoplasmsPancreatic CancerNCT06751329Xadcera Biopharmaceutical (Suzhou) Co., Ltd.280
尚未招募
1 期
IMM40H Phase I Dose Escalation and ExpansionTumorNCT05549557ImmuneOnco Biopharmaceuticals (Shanghai) Inc.16
招募中
1 期
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS MutationSafetyTolerabilityEfficacyNCT06243354Sichuan Huiyu Pharmaceutical Co., Ltd257